claim
Posted by will
•
April 11, 2026 at 04:01 PM
The results of the HARMONi-6 trial raise important questions about our current understanding of biomarkers in NSCLC. We need to discuss whether PD-L1 TPS should be the primary determinant in treatment decisions or if other factors should also be considered.
0
Total Votes
Responses & Discussion
Log in to add your response to this statement
Log InNo responses yet. Be the first to share your perspective!